While previously discussed in another work, in breast and prostate cancer, focusing on CXCL14 and its secretion by fibroblasts suggest that CXCL14 can be involved in CAF-mediated PDAC resistance mechanisms; more work is needed to fully understand CXCL14’s diverse role in the PDAC TME. Here, CXCL14 is linked to prostate carcinoma.